Pharmacogenomic assessment of Mexican and Peruvian populations.
BACKGROUND
Clinically relevant polymorphisms often demonstrate population-specific allele frequencies. Central and South America remain largely uncategorized in the context of pharmacogenomics.


METHODS
We assessed 15 polymorphisms from 12 genes (ABCB1 3435C>T, ABCG2 Q141K, CYP1B1*3, CYP2C19*2, CYP3A4*1B, CYP3A5*3C, ERCC1 N118N, ERCC2 K751Q, GSTP1 I105V, TPMT 238G>C, TPMT 460G>A, TPMT 719A>G, TYMS TSER, UGT1A1*28 and UGT1A1 -3156G>A) in 81 Peruvian and 95 Mexican individuals.


RESULTS
Six polymorphism frequencies differed significantly between the two populations: ABCB1 3435C>T, CYP1B1*3, GSTP1 I105V, TPMT 460G>A, UGT1A1*28 and UGT1A1 -3156G>A. The pattern of observed allele frequencies for all polymorphisms could not be accurately estimated from any single previously studied population.


CONCLUSIONS
This highlights the need to expand the scope of geographic data for use in pharmacogenomics studies.
Faculty of Pharmacy & Pharmaceutical Sciences, 3142F Katz Centre for Pharmacy & Health Research, University of Alberta, Edmonton, AB T6G 2E1, Canada.
Sharon
S
Marsh
Cristi R
CR
King
Derek J
DJ
Van Booven
Jane Y
JY
Revollo
Robert H
RH
Gilman
Howard L
HL
McLeod
D000328:Adult; D000483:Alleles; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D008297:Male; D008800:Mexico / Q000453:epidemiology; D010568:Peru / Q000453:epidemiology; D010597:Pharmacogenetics; D010865:Pilot Projects; D020641:Polymorphism, Single Nucleotide
Hispanic; Mexico; Peru; genotype; pharmacogenomics; polymorphism; population